Effectiveness of Combined Pulmonary Rehabilitation and Progressive Muscle Relaxation in Treating Long-Term COVID-19 Symptoms: A Randomized Controlled Trial.

ingentiumby ingentium

In Clinical Trials Literature.

Publication date: Oct 18, 2024

Background: The aim of this study was to investigate the effects of pulmonary rehabilitation (PR) and additional progressive muscle relaxation (PMR) techniques in patients with long-term COVID-19 symptoms. Methods: We included 61 patients with long COVID-19 symptoms and randomly assigned them to two groups: PR only (group 1 with 30 subjects) and PR with PMR (group 2 with 31 subjects). The PR program consisted of gradual aerobic conditioning, strength training, and breathing exercises. Group 2 received additional 20 min daily sessions of progressive muscle relaxation techniques. Results: Following a 21-day intervention, it was observed that both groups had noteworthy improvements in lung function, exercise capacity, and sleep quality with statistical significance (p < 0. 0001). Group 2 showed significant improvements in overall health (as measured by the General Health Questionnaire-12), patient health (as assessed by the Patient Health Questionnaire-9), general anxiety levels (as indicated by the Generalized Anxiety Disorders Scale-7), and sleep quality (as measured by the Pittsburgh Sleep Quality Index), with statistical significance (p < 0. 0001), compared to group 1. Moreover, the statistical analysis demonstrated no significant difference in exercise capacity improvement between group 1 and group 2, as indicated by a p-value of 0. 1711. Conclusions: The addition of progressive muscle relaxation to pulmonary rehabilitation significantly enhances mental health outcomes, particularly in reducing anxiety and improving sleep quality, for patients with long-term COVID-19 symptoms. These findings suggest that incorporating PMR into PR programs offers a valuable non-pharmacological approach to improving overall patient well-being during long-term COVID-19 recovery.

Open Access PDF

Concepts Keywords
Daily anxiety reduction
Pharmacological exercise capacity
Pittsburgh long COVID-19
Randomized progressive muscle relaxation
pulmonary rehabilitation

Semantics

Type Source Name
disease MESH COVID-19
disease MESH long COVID
disease IDO intervention
disease MESH sleep quality
disease MESH overall health
disease MESH anxiety
disease MESH Anxiety Disorders
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH sequelae
disease MESH brain fog
disease IDO acute infection
disease MESH obesity
disease MESH autoimmune diseases
disease MESH depression
disease MESH symptom clusters
disease MESH musculoskeletal pain
disease MESH chest pain
disease MESH psychological stress
pathway REACTOME Immune System
disease MESH post traumatic stress disorder
disease MESH sleep disorders
disease MESH COPD
drug DRUGBANK Methionine
disease MESH dyspnea
disease MESH infection
disease MESH heart disease
disease MESH hemorrhagic stroke
disease MESH psychiatric disorders
disease MESH respiratory infections
disease MESH chronic pain
drug DRUGBANK Ethanol
disease MESH substance abuse
disease IDO process
drug DRUGBANK Ramipril
drug DRUGBANK Bentiromide
disease MESH psychological well being
disease MESH sleep latency
disease MESH daytime sleepiness
drug DRUGBANK Aspartame
disease MESH General Anxiety Disorder

Original Article

(Visited 1 times, 1 visits today)